Lupin launches combination drug for heart failure patients

19 Jan 2023 , 09:16 AM

Lupin Limited on Wednesday has announced the launch of combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. 

This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg. 

In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure and the estimated prevalence ranges from 1.3 to 4.6 million1, the global pharma major said.

In addition, the HF pattern in India is considered different from the rest of the world2 due to factors such as the average age of Indian patients with HF being 10 years younger than the global average, the high prevalence of hypertension and diabetes, and limited adoption of guideline-directed medical therapy, among others. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, “As a leader in the cardiac therapy area, Lupin is committed to offer patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need, while reducing the cost of therapy.” 

On Thursday early morning trade, Lupin was trading at Rs766.10 per share lower by 0.10% on the BSE.

For feedback and suggestions, write to us at [e-mail]